Relypsa, Inc. is a privately-held, development stage biopharmaceutical company leading the discovery and development of novel non-absorbed polymeric drugs for important applications in cardiovascular and renal disease. Relypsa's lead product candidate is RLY5016, a non-absorbed potassium binder for the management of hyperkalemia.   Relypsa is dedicated to discover additional product candidates through use of its proprietary polymer platform.

BusinessWeek: Venture Capital's Favorite Startups

Disease Information

Pipeline

Press Releases